Orgenesis (NASDAQ:ORGS – Get Free Report) is expected to issue its resultson Friday, August 7th. Analysts expect the company to post earnings of ($2.60) per share and revenue of $2.80 million for the quarter.
Orgenesis Price Performance
NASDAQ ORGS opened at $0.40 on Wednesday. The firm has a market cap of $2.07 million, a P/E ratio of -0.03 and a beta of 3.14. The stock’s 50-day moving average is $0.35 and its 200-day moving average is $0.39. Orgenesis has a one year low of $0.00 and a one year high of $1.00.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Further Reading
- Five stocks we like better than Orgenesis
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
